Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-20-114318
Filing Date
2020-04-22
Accepted
2020-04-22 07:57:37
Documents
8
Effectiveness Date
2020-04-22

Document Format Files

Seq Description Document Type Size
1 DEFA14A d888494ddefa14a.htm DEFA14A 41811
2 GRAPHIC g888494dsp005.jpg GRAPHIC 154606
3 GRAPHIC g888494dsp006.jpg GRAPHIC 211139
4 GRAPHIC g888494dsp007.jpg GRAPHIC 84409
5 GRAPHIC g888494dsp008.jpg GRAPHIC 87290
6 GRAPHIC g888494dsp009.jpg GRAPHIC 259129
7 GRAPHIC g888494dsp010.jpg GRAPHIC 207889
8 GRAPHIC g888494dsp11.jpg GRAPHIC 5376
  Complete submission text file 0001193125-20-114318.txt   1434287
Mailing Address TEVA PHARMACEUTICAL INDUSTRIES LIMITED 5 BAZEL ST PO B 3190 PETACH TIKVA L3 49131
Business Address 5 BAZEL ST P O B 3190 PETACH TIKVA L3 49131 9729267267
TEVA PHARMACEUTICAL INDUSTRIES LTD (Filer) CIK: 0000818686 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-16174 | Film No.: 20806673
SIC: 2834 Pharmaceutical Preparations